Special Issue

Insights into Natural Antimicrobial Peptides

Message from the Guest Editors

The speed of the spread of multidrug resistance (MDR) in both prokaryotic and eukaryotic pathogen organisms is an alarming message for scientists, necessitating a search for ways to block this dangerous trend. The discovery and chemotherapeutic application of novel antimicrobial peptide (AMP) drugs seem to offer a prospective alternative research direction. The arguments for AMPs application include slower emergence of resistance, broad-spectral antibiofilm activity, and the ability to interact synergistically with the host immune system. AMP-resistant bacteria tend to exhibit collateral sensitivity to antibiotics, and the mobility patterns of traditional AMP-resistance genes are different from those of the conventional antibiotics-resistance genes and do not induce drastic changes in the composition of the gut microbiota. As for the publication criteria: original research papers and reviews, - focusing either on theoretical, or application aspects, - reports on discoveries, chemical and biological novelties, application perspectives, bioassays, and synergetic studies are warmly welcome.

Guest Editors

Dr. András Fodor

Dr. Eustachio Tarasco

Dr. Maurizio Francesco Brivio

Deadline for manuscript submissions

31 October 2025

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/184698

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI